Results 11 to 20 of about 1,197 (187)

Novel Pitolisant-Derived Sulfonyl Compounds for Alzheimer Disease

International Journal of Molecular Sciences
Alzheimer’s disease (AD) is a complex and multifactorial neurodegenerative disorder characterized by cognitive decline, memory loss, behavioral changes, and other neurological symptoms.
S. Pérez-Silanes, E. Martišová, E. Moreno, M. Solas, D. Plano, C. Sanmartín, M. Ramírez   +6 more
semanticscholar   +4 more sources

Efficacy and Safety of Histamine H3 Receptor Antagonist/Inverse Agonist Including Betahistine for Schizophrenia: A Systematic Review and Meta‐Analysis

Neuropsychopharmacology Reports
Aim Whether histamine H3 receptor antagonists (H3R‐ANTs)/inverse agonists (H3R‐IAs) provides benefit for the treatment of schizophrenia remains unclear. This meta‐analysis was conducted to address the above clinical question.
Yasufumi Nishii, Kenji Sakuma, Shun Hamanaka, Nakao Iwata, Taro Kishi   +4 more
doaj   +2 more sources

Update on the treatment of narcolepsy: clinical efficacy of pitolisant

Nature and Science of Sleep, 2017
Michael W Calik1,2 1Department of Biobehavioral Health Science, 2Center for Narcolepsy, Sleep and Health Research, University of Illinois at Chicago, Chicago, IL, United States Abstract: Narcolepsy is a neurological disease that affects 1 in 2,000 ...
Calik MW
doaj   +4 more sources

Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the FAERS database

Frontiers in Pharmacology
ObjectiveNarcolepsy, a rare neurological disorder believed to have an autoimmune etiology, necessitates lifelong management. This study aimed to provide evidence supporting the safety of pharmacological treatment for narcolepsy.MethodsFive-year data on ...
Xiaodan Zhou, Jia Chen, Bangtian Xu, Li Chen, Li Chen, Li Chen   +5 more
doaj   +2 more sources

Pitolisant-associated mania – a case report

BMC Neurology
Background Narcolepsy is a chronic neurological disorder treated with medications that promote wakefulness. Pitolisant, a histamine H3 receptor inverse agonist, is used to reduce excessive daytime sleepiness.
Maximilian Zoltek, Richard Ågren
doaj   +2 more sources

Histamine H3 receptor antagonism modulates autism-like hyperactivity but not repetitive behaviors in BTBR T+Itpr3tf/J inbred mice [PDF]

, 2022
Background: Autism spectrum disorders (ASDs) are a group of neurodevelopmental conditions defined by behavioral deficits in social communication and interactions, mental inflexibility and repetitive behaviors.
Hutten, Lianda, Kas, Martien J H, Molenhuis, Remco T   +2 more
core   +1 more source

Pitolisant for Residual Excessive Daytime Sleepiness in OSA Patients Adhering to CPAP A Randomized Trial [PDF]

, 2021
BACKGROUND: Excessive daytime sleepiness (EDS) in individuals with OSA syndrome persisting despite good adherence to CPAP is a disabling condition. Pitolisant is a selective histamine H3-receptor antagonist with wake-promoting effects. RESEARCH QUESTION:
Dauvilliers, Yves, Georgiev, Ognian, HAROSA I Study Grp, Partinen, Markku, Pepin, Jean-Louis, Tiholov, Rumen   +5 more
core   +1 more source

Clinical characteristics of a large cohort of patients with narcolepsy candidate for pitolisant: a cross-sectional study from the Italian PASS Wakix® Cohort [PDF]

, 2022
Introduction: Narcolepsy is a chronic and rare hypersomnia of central origin characterized by excessive daytime sleepiness and a complex array of symptoms as well as by several medical comorbidities.
Agostoni E. C., Blanchard N., Bonanni E., Brunetti V., Centonze D., Cicolin A., Della Marca G., Ferini-Strambi L., Ferri R., Figorilli M., Gigli G. L., Izzi F., Lecomte I., Liguori C., Liguori R., Lodi R., Mutti C., Nobili L., Parrino L., Pedrazzi G., Pizza F., Placidi F., Plazzi G., Proserpio P., Puligheddu M., Romigi A., Sacco T., Savarese M. A., Terzaghi M.   +28 more
core   +5 more sources

Comparison of modafinil and pitolisant in narcolepsy: a non-inferiority metaanalytical approach

Drugs in Context, 2020
Aim: To assess the non-inferiority of pitolisant, a new compound for the relief of excessive daytime sleepiness (EDS) and cataplexy in narcolepsy, compared with modafinil.
Philippe Lehert, Cassandra Szoeke
doaj   +1 more source

The impact of pitolisant, an H3 receptor antagonist/inverse agonist, on perirhinal cortex activity in individual neuron and neuronal population levels

Scientific Reports, 2022
Histamine is a neurotransmitter that modulates neuronal activity and regulates various brain functions. Histamine H3 receptor (H3R) antagonists/inverse agonists enhance its release in most brain regions, including the cerebral cortex, which improves ...
Kyosuke Hirano, Yoshikazu Morishita, Masabumi Minami, Hiroshi Nomura   +3 more
doaj   +1 more source